Flometrica

Disposable, Personalized, Home-use Urine Analyzers

Health Tech & Life Sciences
Private
Follow

Company Overview

Snapshot

Founded in December 2010 by Zeev Cohen, Flometrica operates with 1–10 employees. The company has secured funding across two rounds from two investors, including Medvest and Maayan Ventures, and received a grant from the Office of the Chief Scientist. Flometrica holds a patent for its innovative technology.

Business overview

Flometrica specializes in developing disposable, personalized, and cost-effective urine analyzers for home use or point-of-care settings. Its core technology integrates ergonomic containers with urine sensors connected to a USB micro-controller, with data decrypted by proprietary signal-processing software. The company's products, such as Florite and DiaryRite, are designed to eliminate the need for traditional office-based devices, improving patient diagnostics and providing accurate clinical evaluations to physicians. Flometrica operates within the Digital Medical Diagnostics sector, serving both patients and healthcare providers.

Log in to access full profile

Company Intelligence Q&A

What is Flometrica's primary product?
Flometrica's first product, Florite, is a disposable urine flow meter device designed for 24-hour measurement of flow rate, voiding time, and voiding quantity, featuring a graphical user interface on a smartphone or tablet.
What other product is Flometrica developing?
Flometrica is also developing DiaryRite, a disposable voiding diary and flow meter device for 72-hour measurement of flow rate, voiding time, and voiding quantity, with online monitoring for urine secretion and liquid intake and a graphical user interface on a smartphone or tablet.
When was Flometrica founded?
Flometrica was founded in December 2010.
Who is a co-founder of Flometrica?
Zeev Cohen is a co-founder of Flometrica.
What type of funding did Flometrica receive in February 2018?
In February 2018, Flometrica received funding from investors Medvest and Maayan Ventures.
Log in to access full profile